Category «CHINA 2012»

IMRECOXIB

It’s only fair to share…   Imrecoxib (Hengyang) CHINA 2012  osteoarthritis 2H-Pyrrol-2-one, 1,5-dihydro-3-(4-methylphenyl)-4-[4-(methylsulfonyl)phenyl]-1-propyl- 3-(4-Methylphenyl)-4-[4-(methylsulfonyl)phenyl]-1-propyl-1,5-dihydro-2H-pyrrol-2-one   395683-14-4 [RN] Imrecoxib was approved by China Food and Drug Administration (CFDA) on May 20, 2011. It was developed and marketed as 恒扬® by HengRui Pharmaceuticals. Imrecoxib is a selective COX-2 inhibitor indicated for treatment of osteoarthritis. 恒扬® is available as tablet for …